The conventional valine-citrulline linker has some intrinsic drawbacks associated with long standing challenges in ADC stability and efficacy. The exo-cleavable linkers reposition the peptide sequence at an outer (exo) orientation. This novel structural shift provides several advantages over regular Val-Cit peptide linker and demonstrates great in-vivo performance 1. Precise controlled release with minimal pre-mature payload cleavage 2. Hydrophilic peptide sequence remarkably improve stability by reducing aggregation 3. High DAR constructs can be achieved even with hydrophobic payloads without inducing aggregation. Various payloads and linker functionalization are available upon request.
Usually ships within 24 hours.